Persistencia en el tratamiento según el tipo de dispositivo inhalador en pacientes con asma y enfermedad pulmonar obstructiva crónica

Sicras, Antoni; Ferrer, Vicenç Falcó; Collar, J.M.; Navarro, R; Sáez, María Isabel Corbí

doi:10.1016/j.semerg.2016.05.008

Cited by 5 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhaler devices may influence patient compliance with long-term asthma medication regimens (Darbà et al., 2016 ). pMDI devices such as those used for ICS/LABA initial treatment are associated with longer treatment persistence and better treatment adherence in asthma, as well as lower exacerbation rates, reduced use of health resources and lower costs (Sicras et al., 2016 ). We studied pMDIs without a spacer in the present study.…”

Section: Discussionmentioning

confidence: 99%

Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?

et al. 2017

View full text Add to dashboard Cite

Two main types of devices are used to facilitate the administration of inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) in combination, dry powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs). There are few reports comparing the effects of the two devices, and it is unknown which should be recommended for asthma patients with given sets of characteristics. In the current study, the beneficial effects and side effects associated with DPIs and pMDIs were compared, and the question of which device should be recommended for asthma patients was investigated. A prospective, randomized, crossover, comparative study in adult outpatients with asthma was conducted using salmeterol/fluticasone propionate combination (SFC) 50 μg/250 μg, one inhalation of Adoair 250 Diskus twice daily or two inhalations of Adoair 125 Aerosol twice daily, for 8 weeks. Questionnaires, exhaled nitric oxide (FeNO) tests and pulmonary function tests were administered after the use of each device for 8 weeks, and the results derived from each device were compared. Sixty-eight subjects were included in the final analysis. There were no significant differences between quality-of-life scores, FeNO, spirometry test results and forced oscillation results. With regard to patient preferences, 57.4% preferred the Adoair Aerosol and 35.3% preferred the Adoair Diskus, as determined via the comparative evaluation questionnaire. Although DPI prescription accounts for the predominant market share of combined ICS/LABA in Japan, patients preferred a pMDI device to a DPI device. Compared to DPIs, pMDIs may be the preferential choice for patients with asthma.

show abstract

Section: Discussionmentioning

confidence: 99%